Speciality Medicines Ltd

Speciality Medicines Limited maintains a strong liquidity position, with a current ratio of 5.5, indicating that it has more than five times the current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which raises concerns about its short-term liquidity. The company's debt-to-equity ratio is 0.16, suggesting a relatively low level of leverage compared to industry norms. In terms of profitability, the company reports a return on equity (ROE) of 23.5% and a return on assets (ROA) of 17.98%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that the company is generating substantial returns relative to its equity and asset base. The operating margin, calculated as operating income divided by revenue, is 15.26%, which is a key metric for assessing operational efficiency in the pharmaceutical industry. The company's revenue is derived from the domestic market, where it sources existing Indian medicine brands from manufacturers and their authorized distributors. While the company does not disclose specific segment or geographic revenue breakdowns, its business model is heavily concentrated in the domestic market, which may expose it to regional economic and regulatory risks. Looking at the growth trajectory, the company's revenue for the latest period is INR 582.71 million. While the outlook for the current fiscal year is not explicitly provided, the company's free cash flow of INR 67.87 million indicates that it is generating positive cash from operations after capital expenditures. The company's operating cash flow is negative at INR -64.32 million, which may be due to timing differences in cash inflows and outflows or increased working capital requirements. The company faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. However, the company's capital structure and liquidity position should be closely monitored for any changes that could affect its financial stability. Recent events and filings have not been disclosed in the provided data, so no specific recent developments can be cited. The company's financial and operational performance is primarily based on the latest financial snapshot and valuation metrics.